Table 2 Psychological characteristics of the study population
From: Antinuclear antibody and rheumatoid factor positivity in temporomandibular disorders
|  | Total patients (n = 257) | Male patients (n = 51) | Female patients (n = 206) | ||||||
|---|---|---|---|---|---|---|---|---|---|
ANA/RF (+) (n = 39) | ANA/RF (−) (n = 218) | P-value | ANA/RF (+) (n = 4) | ANA/RF (−) (n = 47) | P-value | ANA/RF (+) (n = 35) | ANA/RF (−) (n = 171) | P-value | |
RDC SOM | 0.54 (0.08–1.20) | 0.58 (0.17–1.25) | 0.938 | 0.79 (0.27–1.56) | 0.33 (0–0.92) | 0.258 | 0.54 (0.08–1.17) | 0.67 (0.25–1.29) | 0.424 |
RDC PSOM | 0.36 (0–0.91) | 0.43 (0–1.07) | 0.732 | 0.58 (0–18-1.61) | 0.17 (0–0.70) | 0.214 | 0.36 (0–0.89) | 0.57 (0.14–1.14) | 0.297 |
RDC DEP | 0.60 (0.24–1.11) | 0.55 (0.1–1.2) | 0.606 | 0.50 (0.06–0.98) | 0.20 (0–0.85) | 0.798 | 0.60 (0.28–1.18) | 0.64 (0.14–1.3) | 0.822 |
SOM | 43 (40–52) | 43 (40–50) | 0.546 | 48 (44–62) | 43 (40–50) | 0.142 | 43 (40–52) | 43 (39–50) | 0.801 |
O-C | 42 (38–53) | 42 (36–49) | 0.381 | 46 (38–52) | 41 (35–49) | 0.529 | 42 (38–54) | 42 (36–49) | 0.473 |
I-S | 41 (36–55) | 41 (36–48) | 0.762 | 47 (35–58) | 40 (36–49) | 0.736 | 41 (36–52) | 41 (36–48) | 0.840 |
DEP | 41 (35–52) | 40 (36–47) | 0.879 | 41 (35–58) | 39 (36–47) | 0.966 | 41 (34–52) | 41 (35–47) | 0.992 |
ANX | 43 (37–50) | 40 (38–48) | 0.322 | 51 (39–61) | 40 (39–50) | 0.369 | 43 (37–50) | 41 (38–47) | 0.395 |
HOS | 43 (40–48) | 43 (40–48) | 0.651 | 47 (40–58) | 42 (40–49) | 0.595 | 43 (40–48) | 43 (40–48) | 0.737 |
PHOB | 42 (40–48) | 42 (40–48) | 0.749 | 44 (41–62) | 43 (43–45) | 0.822 | 42 (40–48) | 42 (40–48) | 0.427 |
PAR | 40 (38–42) | 40 (38–42) | 0.736 | 47 (39–56) | 40 (38–42) | 0.324 | 40 (38–42) | 40 (38–43) | 0.995 |
PSY | 40 (38–52) | 41 (38–46) | 0.960 | 47 (39–58) | 40 (40–45) | 0.555 | 39 (38–47) | 41 (38–46) | 0.799 |